Skip to main content
SpringerLink
Log in

Chemoprevention of breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Despite a recent trend toward improvement in the U.S. breast cancer mortality rate, breast cancer incidence (182,800 new cases anticipated in 2000) and mortality figures (over 40,800 anticipated deaths) remain the highest and second highest, respectively, of all cancers in U.S. women. In 1998, the selective-estrogen-receptor-modulator (SERM) tamoxifen achieved positive results in the Breast Cancer Prevention Trial (BCPT), leading to the Food and Drug Administration (FDA) approval of tamoxifen for risk reduction in women at high risk of breast cancer (the historic first FDA approval of a cancer preventive agent). This brought about a paradigm shift in new approaches for controlling breast cancer toward pharmacologic preventive regimens, called chemoprevention. This paper presents a comprehensive clinical review of breast cancer prevention study, highlighting issues of the extensive study of tamoxifen. These issues include the record of primary tamoxifen results in several breast-cancer risk-reduction settings (primary, adjuvant, and ductal carcinoma in situ [DCIS]); critical secondary BCPT risk-benefit findings (including quality of life issues) and their effects on counseling patients on use of tamoxifen for prevention; ethic minorities; optimal tamoxifen dose/duration; and potential impact on mortality and other issues involved with potential net benefit to society. Other breast-cancer chemoprevention issues reviewed here include women at high genetic risk (especially BRCA1 mutation carriers); raloxifene in breast cancer prevention; other SERMs; SERM resistance; and new agents and combinations currently in development. Very recent developments involving PPAR-γ ligands, COX-2 inhibitors, and RXR-ligands are discussed in the section on new drug development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7–33, 2000

    Google Scholar 

  2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM et al.: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 90: 1371–1388, 1998

    Google Scholar 

  3. Jordan VC, Morrow M: Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20: 253–278, 1999

    Google Scholar 

  4. Dhingra K: Antiestrogens–tamoxifen, SERMs and beyond. Invest New Drugs 17: 285–311, 1999

    Google Scholar 

  5. Lippman SM, Brown PH: Tamoxifen prevention of breast cancer: an instance of the fingerpost. J Natl Cancer Inst 91: 1809–1819, 1999

    Google Scholar 

  6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451–1467, 1998

    Google Scholar 

  7. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M et al.: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98–101, 1998

    Google Scholar 

  8. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C et al.: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352: 93–97, 1998

    Google Scholar 

  9. Wolmark N, Dignam J, Fisher B: The addition of tamoxifen to lumpectomy and radiotherapy in the treatment of ductal carcinoma in situ (DCIS): preliminary results of NSABP protocol B-24. Breast Cancer Res Treat 50: Abstract 1, 1998

  10. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E et al.: Tamoxifen in treatment of intraductal breast cancer: national surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 353: 1993–2000, 1999

    Google Scholar 

  11. Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90: 1514–1528, 1998

    Google Scholar 

  12. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609–1618, 1998

    Google Scholar 

  13. Jordan VC: Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst 90: 967–971, 1998

    Google Scholar 

  14. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ et al.: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552–1558, 1998

    Google Scholar 

  15. Narod S: Letter: Re: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 91: 188, 1999

    Google Scholar 

  16. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992

    Google Scholar 

  17. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF et al.: Bone mass and the risk of breast cancer among postmenopausal women. N Engl J. Med 336: 611–616, 1997

    Google Scholar 

  18. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Clin Oncol 17: 2659–2669, 1999

    Google Scholar 

  19. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP et al.: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 82: 1327–1332, 1990

    Google Scholar 

  20. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular systesm. N Engl J Med 340: 1801–1811, 1999

    Google Scholar 

  21. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613, 1998

    Google Scholar 

  22. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279: 688–695, 1998

    Google Scholar 

  23. Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B: Base-line quality of life assessment in the National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial. J Natl Cancer Inst 87: 1372–1382, 1995

    Google Scholar 

  24. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG: American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 17: 1939–1955, 1999

    Google Scholar 

  25. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V: Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829–1846, 1999

    Google Scholar 

  26. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al.: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529–1542, 1996

    Google Scholar 

  27. Fisher B: National surgical adjuvant breast and bowel project breast cancer prevention trial: a reflective commentary. J Clin Oncol 5: 1632–1639, 1999

    Google Scholar 

  28. Rockhill B, Colditz G, Kaye J: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 657–658, 2000

    Google Scholar 

  29. Lippman SM, Brown PH: Response: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 658–659, 2000

    Google Scholar 

  30. Fisher B: Response: Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost [letter]. J Natl Cancer Inst 92: 659–660, 2000

    Google Scholar 

  31. Phillips K, Glendon G, Knight JA: Putting the risk of breast cancer in perspective. N Engl J Med 340: 141–143, 1999

    Google Scholar 

  32. Page DL, Simpson JF: Ductal carcinoma in situ — The focus for prevention, screening, and breast conservation in breast cancer. N Engl J Med 340: 1499–1500, 1999

    Google Scholar 

  33. Fisher ER, Fisher B: Relation of a recurrent intraductal carcinoma (ductal carcinoma in situ) to the primary tumor. J Natl Cancer Inst 92: 288–289, 2000

    Google Scholar 

  34. Wilcken NR: Tamoxifen hits the target in situ. Lancet 12: 353, 1986–dy1987, 1999

    Google Scholar 

  35. Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B et al.: Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol 17: 2633–2683, 1999

    Google Scholar 

  36. Taylor Al, Adams-Campbell LL, Wright JT Jr: Risk/benefit assessment of tamoxifen to prevent breast cancer – still a work in progress? [editorial]. J Natl Cancer Inst 91: 1792–1793, 1999

    Google Scholar 

  37. Taylor AL, Adams-Campbell LL, Wright JT Jr: Response: Re: Risk/benefit assessment of tamoxifen to prevent breast cancer – still a work in progress? [letter]. J Natl Cancer Inst 92: 574–575, 2000

    Google Scholar 

  38. McCaskill-Stevens W, Bryant J, Costantino J, Wickerham DL, Vogel V, Wolmark N et al.: Incidence of contralateral breast cancer (CBC), endometrial cancer (EC), and thromboembolic events (TE) in African American (AA) women receiving tamoxifen for treatment of primary breast cancer [abstract]. Proc ASCO 19: 70a, 2000

    Google Scholar 

  39. Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, Brunet JS, Narod SA: Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354: 1846–1850, 1999

    Google Scholar 

  40. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Esaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475–1479, 1999

    Google Scholar 

  41. Loman N, Johannsson O, Bendahl PA, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83: 310–319, 1998

    Google Scholar 

  42. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A et al.: Distinct molecular pathogeneses of earlyonset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59: 2011–2017, 1999

    Google Scholar 

  43. Hartmann J, Schaid D, Woods J, Crotty T, Myers J, Arnold P et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77–84, 1999

    Google Scholar 

  44. Eisen A, Weber BL: Prophylactic mastectomy – The price of fear. N Engl J Med 340: 137–138, 1999

    Google Scholar 

  45. Brown P, Fuqua S, Allred C: Pathogenesis of estrogen receptor positive and negative breast cancer. In: Ethier SP, (ed). Contemporary Endocrinology: Endocrine Oncology. Totowa (NJ): Humana Press. p. 49–68, 2000

    Google Scholar 

  46. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR et al.: BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354–1356, 1999

    Google Scholar 

  47. Osin P, Crook T, Powles T, Peto J, Gusterson B: Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 351: 1487, 1998

    Google Scholar 

  48. Jordan VC: How is tamoxifen's action subverted? J Natl Cancer Inst 92: 92–93, 2000

    Google Scholar 

  49. Radmacher MD, Simon R: Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. J Natl Cancer Inst 92: 48–53, 2000

    Google Scholar 

  50. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281: 2189–2197, 1999

    Google Scholar 

  51. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A et al.: Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double-blind, placebocontrolled, randomized trials in postmenopausal women. Breast Cancer Res Treat 50: Abstract 2, 1998

  52. Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12: 851–873, 1994

    Google Scholar 

  53. O'Shaughnessy J: Chemoprevention of breast cancer. JAMA 275: 1349–1353, 1996

    Google Scholar 

  54. Mehta RG, Williamson E, Patel MK, Koefflex HP: A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92: 418–423, 2000

    Google Scholar 

  55. Harris RE, Alshafie GA, Hussen A-I, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101–2103, 2000

    Google Scholar 

  56. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM: Retinoid receptor-dependent and-independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59: 14–18, 1999

    Google Scholar 

  57. Sun S-Y, Li W, Yue P, Lippman SM, Hong WK, Lotan R: Mediation of N-(4-hydroxyphenyl)retinamide-induced apoptosis in human cancer cells by different machanisms. Cancer Res 59: 2493–2498, 1999

    Google Scholar 

  58. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A et al.: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856, 1999

    Google Scholar 

  59. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee JJ et al.: Suppression of retinoic acid receptor beta in oral premalignant lesions and its upregulation by isotretinoin. N Engl JMed 332: 1405–1410, 1995

    Google Scholar 

  60. Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukmanji F et al.: Progressive decrease in nuclear retinoic acid receptor b messenger RNA level during breast carcinogenesis. Cancer Res 57: 4992–4996, 1997

    Google Scholar 

  61. Widschwendter M, Berger J, Daxenbichler G, Muller Holzner E, Widschwendter A, Mayr A et al.: Loss of retinoic acid receptor b expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue. Cancer Res 57: 4158–4161, 1997

    Google Scholar 

  62. Kuppumbatti YS, Bleiweiss IJ, Mandeli JP, Wasman S, Mira-Y-Lopez R: Cellular retinol-binding protein expression and breast cancer. J Natl Cancer Inst 92: 475–480, 2000

    Google Scholar 

  63. Spinella MJ, Dmitrovsky E: Aberrant retinoid signaling and breast cancer: the view from outside the nucleus. J Natl Cancer Inst 92: 438–440, 2000

    Google Scholar 

  64. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW: Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) cause complete regression of mammary carcinoma. Cancer Res 58: 479–484, 1998

    Google Scholar 

  65. Bischoff ED, Heyman RA, Lamph WW: Effect of the retinoid X receptor-selective ligand LGD 1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91: 2118, 1999

    Google Scholar 

  66. Nunez SB, Medin JA, Braissant O, Kemp L, Wahli W, Ozato K et al.: Retinoid X receptor and peroxisome proliferateractivated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol Cell Endocrinol 127: 27–40, 1997

    Google Scholar 

  67. Chen TK, Smith LM, Gebhardt D, Birrer MJ, Brown PH: Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog 15: 215–226, 1996

    Google Scholar 

  68. Smith LM, Birrer MJ, Stampher MR, Brown PH: Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res 57: 3046–3054, 1997

    Google Scholar 

  69. Yang LM, Kim HT, Munoz-Medellin D, Reddy P, Brown PH: Induction of retinoid resistance in breast cancer cells by overexpression of cJun. Cancer Res 57: 4652–4661, 1997

    Google Scholar 

  70. Yu W, Simmons-Menchaca M, You H, Brown PH, Birrer M, Sanders B, et al.: RRR-α-tocopheryl succinate induces prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog 22: 247–257, 1998

    Google Scholar 

  71. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Brown PH, Birer MJ: cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063–6070, 1999

    Google Scholar 

  72. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M et al.: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251–256, 1999

    Google Scholar 

  73. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG et al.: Tamoxifen-stimulated breast tumor growth in vivo is associated with oxidative stress and increased AP-1 activity. J Natl Cancer Inst (in press)

  74. Yang L, Munoz-Medellin D, Kim HT, Ostrowski J, Reczek P, Brown PH: Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. Breast Cancer Res Treat 56: 277–291, 1999

    Google Scholar 

Download references

Authors
  1. Powel H. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott M. Lippman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, P.H., Lippman, S.M. Chemoprevention of breast cancer. Breast Cancer Res Treat 62, 1–17 (2000). https://doi.org/10.1023/A:1006484604454

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006484604454

Search

Navigation